Get the Stockscreener App
42.61
3.27%
1.35
Vera Therapeutics Inc stock is traded at $42.61, with a volume of 1.57M.
It is up +3.27% in the last 24 hours and up +74.99% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$41.26
Open:
$41.22
24h Volume:
1.57M
Relative Volume:
1.01
Market Cap:
$2.72B
Revenue:
-
Net Income/Loss:
$-218.28M
P/E Ratio:
-11.90
EPS:
-3.5803
Net Cash Flow:
$-186.55M
1W Performance:
+27.84%
1M Performance:
+74.99%
6M Performance:
+33.18%
1Y Performance:
-13.85%
1-Day Range:
$39.87
$43.39
1-Week Range:
$32.66
$43.39
52-Week Range:
$18.53
$49.77
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
42.61 | 2.64B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics exec Turner sells $400k in shares - Investing.com
Will Vera Therapeutics Inc. stock reach Wall Street targets2025 Institutional Moves & Consistent Growth Stock Picks - Newser
Why Vera Therapeutics Inc. stock is trending among retail tradersMarket Volume Summary & Short-Term Trading Opportunity Alerts - Newser
Is Vera Therapeutics’ Recent 69% Surge Justified by Its Valuation in 2025? - Yahoo Finance
Vera Therapeutics Inc. (VERA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vera Therapeutics Stock Soars: Time to Buy? - StocksToTrade
Vera Therapeutics (VERA): Reassessing Valuation After Positive Phase 3 IgAN Data and Accelerated FDA Path - Yahoo Finance
Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment? - Yahoo Finance
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.7%Here's What Happened - MarketBeat
Vera Therapeutics, Inc. (VERA): A Top Gainer with Promising FDA Approvals - Meyka
Vera Therapeutics: Stock Rises As IgAN Approval Chances IncreaseI'm On Sidelines (VERA) - Seeking Alpha
American Century Companies Inc. Raises Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Why Vera Therapeutics Stock Rocked the Market on Tuesday - Finviz
Vera Therapeutics stock price target reiterated at $73 by Raymond James - Investing.com Canada
Vera’s Surge: What It Means For Investors - timothysykes.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Quadrature Capital Ltd Invests $852,000 in Vera Therapeutics, Inc. $VERA - MarketBeat
Why Vera Therapeutics Inc. stock is recommended by analystsWeekly Profit Summary & Safe Entry Trade Reports - Newser
Discipline and Rules-Based Execution in VERA Response - news.stocktradersdaily.com
Vera Therapeutics Contributes To Nasdaq Index Growth In Biotech - Kalkine Media
XTX Topco Ltd Grows Position in Vera Therapeutics, Inc. $VERA - MarketBeat
A Fresh Look at Vera Therapeutics (VERA) Valuation as Analyst Optimism Follows Board Addition and FDA Milestone - sahmcapital.com
Vera Therapeutics stock steady as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Wolfe Research Initiates Coverage of Vera Therapeutics (VERA) with Outperform Recommendation - MSN
Polycythemia Vera Pipeline 2025: MOA and ROA Insights, Clinical - openPR.com
Earnings Report: Is Vera Therapeutics Inc. stock a top momentum play2025 Short Interest & AI Based Buy and Sell Signals - BỘ NỘI VỤ
Vera Thera files BLA for atacicept in IgAN - The Pharma Letter
Why Vera Therapeutics Stock Crushed it Today - Finviz
Vera Therapeutics appoints former Gilead executive to board By Investing.com - Investing.com Nigeria
Vera Therapeutics Appoints James R. Meyers to Board - TipRanks
Vera Therapeutics Stock Unveiled: What Lies Ahead? - timothysykes.com
Vera Therapeutics Form 4 shows 25,000 director stock options - Stock Titan
New Vera Therapeutics (VERA) director reports zero beneficial ownership - Stock Titan
Vera Therapeutics Appoints James R. Meyers to Board of Directors - TradingView
[8-K] Vera Therapeutics, Inc. Reports Material Event | VERA SEC FilingForm 8-K - Stock Titan
Vera Therapeutics appoints former Gilead executive to board - Investing.com
Vera Therapeutics Appoints Biopharmaceutical Veteran James R. Meyers to Board of Directors - Quiver Quantitative
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors - GlobeNewswire
After pivot, this Bay Area CEO says company is hiring and 'almost to the starting line'San Francisco Business Times - The Business Journals
Vera Therapeutics stock undervalued with strong IgAN market potential By Investing.com - Investing.com UK
Vera Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Vera Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Officer Carter Files To Sell 3,864 Of Vera Therapeutics Inc [VERA] - TradingView
Vera Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Vera Therapeutics to Present at Upcoming Investor Conferences in December 2025 - Quiver Quantitative
Vera Therapeutics (Nasdaq: VERA) joins Evercore and Citi 2025 healthcare investor events - Stock Titan
The Bull Case For Vera Therapeutics (VERA) Could Change Following Positive Phase 3 Atacicept Kidney Data - sahmcapital.com
BK Virus Infection Market Trends, Strategies and Business Prospects 2025-2035 - GlobeNewswire Inc.
Will Vera Therapeutics Inc. stock benefit from automation2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
How high can Vera Therapeutics Inc. stock goJuly 2025 Intraday Action & Daily Chart Pattern Signals - newser.com
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):